Kindeva Drug Delivery

What Kindeva Drug Delivery does

Kindeva Drug Delivery is a global contract development and manufacturing organization (CDMO) specializing in drug-device combination products across injectable, inhalation, nasal, and dermal platforms. Originating as the drug delivery business of 3M and operating as an independent company since the 2015 spin-off under private equity owner Altaris Capital Partners, Kindeva runs roughly 1 million square feet of cGMP manufacturing and R&D capacity across more than ten sites in the United States and United Kingdom, employs approximately 2,000 people, and ships on the order of 100 million commercial devices per year. The company pioneered the pressurized metered-dose inhaler (pMDI) in 1956, holds roughly 1,300 patents with 75 inventions in commercial use, and serves customers in more than 30 countries spanning pharmaceutical and biotech sponsors as well as government and military health agencies.

The company's core technology platforms cover sterile injectable fill-finish (including isolator-based lines with automated controls and real-time process monitoring), inhalation drug-device products (pMDIs, dry powder, and low-global-warming-potential propellant programs), nasal spray drug-device systems, microneedle and transdermal delivery, and autoinjectors (with more than 250 million units manufactured cumulatively since 1958). Recent capital projects include a ~$200 million Bridgeton, MO sterile fill-finish facility built to Annex 1 standards and a new UK headquarters at the Charnwood Campus opened in September 2025; commercial-scale low-GWP propellant manufacturing lines were stood up in 2024–2025 to serve the regulatory transition away from legacy HFA propellants.

Kindeva makes money by charging pharmaceutical, biotech, and government/military customers for development, clinical supply, and commercial manufacturing services across its drug-device combination platforms under multi-year program and supply agreements. Revenue mechanics combine fee-for-service development work with high-margin commercial contract manufacturing once a sponsor's combination product is approved. Go-to-market is anchored by deep regulatory expertise, a track record of first-in-category approvals, and a sponsor base that includes both large pharma partners and emerging biotechs; visible recent commercial relationships include the Scienture Holdings manufacturing partnership for REZENOPY. The 2026 Veeva Quality Cloud partnership and a recently appointed CEO (David Stevens, effective January 1, 2026) underscore ongoing operational scaling rather than restructuring.

Name

Kindeva Drug Delivery

Legal name

Kindeva Drug Delivery L.P.

Website

https://kindevadd.com

Company type

Private

Founded year

1956

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)

Keywords

• Contract drug manufacturing
• Drug-device combination products
• Sterile injectable fill-finish
• Inhalation drug delivery
• Pulmonary nasal dermal delivery

Headquarters

HQ city

Saint Paul

HQ country

United States

HQ region

North America

Offices10 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing (CDMO) Services: Kindeva generates revenue through comprehensive CDMO services for pharmaceutical companies including development, manufacturing, analytical testing, fill-finish, regulatory support, and post-commercialization services. Revenue is earned through long-term contracts with pharmaceutical and biotech clients for drug-device combination products across injectable, inhalation, nasal, and dermal platforms.
2. Manufacturing and Commercial Supply: Revenue from manufacturing drug products for clients including commercial supply of approved therapies. Summit Biosciences Inc., a subsidiary of Kindeva Drug Delivery L.P., manufactures REZENOPY (naloxone HCl) nasal spray 10mg for Scienture Holdings.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Kindeva Drug Delivery is a global contract development and manufacturing organization (CDMO) specializing in drug-device combination products. The company provides end-to-end development, manufacturing, analytical, fill-finish, regulatory, and post-commercialization services across sterile injectable, pulmonary, nasal, and dermal drug delivery platforms, anchored by proprietary technologies including pMDIs, autoinjectors, microneedle array patches, nasal sprays, and transdermal patches.

Product overview

Kindeva Drug Delivery is a global contract development and manufacturing organization (CDMO) offering integrated drug-device combination products and services across injectable, pulmonary, nasal, and dermal delivery platforms. The company's core offerings include: (1) Autoinjector platforms (TruJect™, BinaJect®, ComboPen®, AtroPen®) for sterile injectables with 150M+ annual unit capacity; (2) Pulmonary delivery systems including pMDIs, DPIs, soft mist inhalers, and nebulizers; (3) Nasal spray drug delivery with full-service manufacturing at Lexington, KY; (4) Dermal delivery including transdermal patches and microneedle array patches; and (5) Comprehensive CDMO services spanning development, analytical testing, regulatory support, fill-finish, and post-commercialization. The company operates 10 manufacturing and R&D facilities across the US and UK with a ~1 million sq. ft. cGMP footprint, having invested $200M+ in the Bridgeton, MO aseptic fill-finish facility. Kindeva pioneered the pMDI in 1956 and continues driving innovation through green propellant development and strategic acquisitions like iPharma Labs (2022) for enhanced inhalation capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• Meridian Medical Technologies: The global health security business unit within Kindeva Drug Delivery, providing medical countermeasures to protect military personnel, first responders, and civilians.

Products and services

• Sterile Injectables (Fill-Finish Services and Injectable Device Expertise) Aseptic fill-finish services and injectable device expertise supporting vial, cartridge, and prefilled syringe programs with 150M+ units of annual capacity at the Bridgeton, Missouri facility for pharmaceutical and biotech companies.
• TruJect™ Platform Single-chamber autoinjector platform with integrated sharps protection, providing easy and reliable self-administration for a variety of medications.
• BinaJect® Platform Dual-chamber autoinjector platform that enhances stability for intramuscular injections by keeping drugs separated in vitro and in vivo.
• ComboPen® Platform Autoinjector platform designed to deliver medical countermeasures efficiently in the field while navigating complex regulations.
• AtroPen® Autoinjector Platform Emergency autoinjector platform providing fast, reliable self-injection options used by military and NASA in the Project Mercury spaceflight program in 1961.
• Pressurized Metered-Dose Inhalers (pMDIs) Inhalation drug delivery devices that deliver medication directly to the lungs, supporting propellant-based suspensions and solutions with multi-dose capabilities, including CFC-free and low-GWP propellant formulations.
• Dry Powder Inhalers (DPIs)
• Soft Mist Inhalers (SMIs)
• Nebulizers Inhalation devices for delivering aqueous formulations using off-the-shelf nebulizers, featuring silent operation, simple controls, and discreet portability.
• Nasal Spray Drug Delivery Full-service nasal drug delivery solutions including pMDIs, DPIs, and nasal sprays for local, systemic, and nose-to-brain drug delivery at the Lexington, Kentucky facility.
• Transdermal Patches Drug-in-adhesive patches providing non-invasive drug delivery over extended timeframes, including single-layer, multi-layer, and active gel patch formulations.
• Microneedle Array Patches Intradermal drug delivery platforms for small and large molecules including vaccines, peptides, proteins, and biologics, offering potential elimination of cold-chain storage and enhanced immunogenicity.
• Aseptic Fill-Finish Services Annex 1-aligned, isolator-based sterile fill-finish services with over 150 million doses released to patients worldwide, supporting vials, prefilled syringes, and cartridges.
• Quality Management & Compliance Services Quality by Design (QbD) embedded services ensuring compliance with cGMP guidelines including CFR 210, CFR 211, CFR 820, 21 CFR Part 4, and ICH Q1A through Q10.
• Regulatory Services Comprehensive regulatory support including CMC consulting, submission dossier preparation, eCTD publishing, and strategic guidance for FDA, EMA, and international regulatory frameworks.
• Analytical Testing Services Comprehensive analytical testing including method development, raw material qualification, stability testing, extractables and leachables testing, container closure integrity testing, and elemental impurity control.
• Global Health Security (Meridian Medical Technologies) Medical countermeasures business unit providing emergency treatments and autoinjector technology to protect military personnel, first responders, and civilians, with manufacturing of over 250 million autoinjectors since 1958.
• Low-GWP Green Propellant Development and Manufacturing Next-generation propellant development and manufacturing for low-GWP (Global Warming Potential) inhalers, including HFA152a and HFO1234ze propellants with up to 99.9% lower GWP.

Quantifiable outcome

• ~100M commercial devices shipped annually
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Veeva SystemscoreTechnology or Integration · 28 May 2026Kindeva adopted Veeva Quality Cloud to modernize manufacturing operations across its global network of sites. The platform integrates Veeva QualityDocs, QMS, Training, and LearnGxP to standardize quality processes, enable real-time visibility, ensure regulatory compliance, and support operational efficiency across fill-finish operations. This partnership helps Kindeva unify quality management, documentation, and training operations onto a single cloud platform.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Catalent (Novo Holdings): Global CDMO with overlapping capabilities in sterile injectables, soft mist and metered-dose inhalers, autoinjectors and nasal drug delivery. Catalent is the closest direct competitor, recently acquired by Novo Holdings for ~$16B, serving many of the same pharma and biotech customers.
• West Pharmaceutical Services: Supplier of drug delivery devices, elastomer components, and containment solutions for injectable and inhalation products. Comparable to Kindeva through its device-side expertise in autoinjectors, prefilled syringe systems, and inhalation components, though less vertically integrated into formulation and fill-finish services.
• AptarGroup: Drug delivery device specialist serving pharmaceutical and consumer health customers with pumps, valves, and inhalation/nasal devices (pMDI, DPI, nasal spray). Directly competes with Kindeva in inhalation and nasal device platforms, including low-GWP propellant development initiatives.
• Hovione: Portugal-based CDMO with deep inhalation (pMDI, DPI) and sterile injectable capabilities, plus particle engineering and formulation development. Comparable to Kindeva across both inhalation drug substance and drug product services for pulmonary and nasal therapies.
• Bespak (Recipharm): UK-based drug delivery device manufacturer specializing in pMDI valves, dose counters, and inhalation/nasal components, now part of Recipharm. Directly comparable to Kindeva in pMDI component manufacturing and propellant-based delivery technology.
• Recipharm: European CDMO offering sterile fill-finish, inhalation, and oral solid dose services. Comparable to Kindeva in sterile injectables and inhalation CDMO offerings, with Bespak device capabilities now extending overlap in pMDI manufacturing.

Broad incumbents

• Lonza: One of the largest global CDMOs across biologics, small molecules, and cell/gene therapy. Overlaps with Kindeva in sterile fill-finish and complex parenteral manufacturing, though with a much broader and deeper biologics portfolio rather than inhalation specialty.
• Patheon (Thermo Fisher Scientific): Global pharma services division of Thermo Fisher offering drug substance, drug product, sterile fill-finish and clinical packaging. Comparable to Kindeva in sterile injectable manufacturing scale, though broader and less specialized in inhalation and drug-device combinations.
• Samsung Biologics: Large-scale biologics CDMO with significant fill-finish capacity. Comparable to Kindeva in aseptic fill-finish for complex injectables, particularly biologics, though without Kindeva's inhalation, nasal, or dermal specialization.

Emerging players

• Medincell: French pharmaceutical company developing long-acting injectable drug delivery using biodegradable polymer technology. Comparable to Kindeva in novel drug-device injectable platforms, though at an earlier commercial stage and with a narrower technology focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks3 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kindeva-drug-delivery

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kindeva Drug Delivery